Measurement of the Second Gas Effect on Sevoflurane in Anaesthetised Patients
|Study Design:||Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Crossover Assignment
Masking: Open Label
|Official Title:||Measurement of the Second Gas Effect on Sevoflurane in Anaesthetised Patients|
- Fa/FI sevoflurane in 100% O2 vs in 70% N2O and 30% O2 during 1st 60 min anaesthesia
- Change in Fa/FI sevoflurane in 100% O2 vs in 70% N2O and 30% O2 after 60 minutes anaesthesia
- Fa/FI and FA/FI for N2O will also be recorded.
|Study Start Date:||May 2006|
|Study Completion Date:||September 2006|
|Experimental: N2O||Drug: Administration of N2O|
|Placebo Comparator: No N2O||Drug: No nitrous oxide|
This study is investigating the "second gas effect", a phenomenon produced by the uptake of nitrous oxide (N2O) by the lungs, during the course of a typical anaesthetic. The effect is to increase the concentration of other breathed gases in the lung. These include oxygen and volatile anaesthetic agents such as sevoflurane, which are also normally administered along with N2O.
While the second gas effect has been demonstrated previously, by measuring the concentration of volatile anaesthetic in the expired breath, no study has yet shown that it has a significant effect on the concentrations in the blood. The blood concentration is in fact more important, as it directly determines the concentration of anaesthetic reaching the brain, and therefore the effect on the depth of anaesthesia. The second gas effect on blood concentrations may be more powerful than that on expired concentrations, due to the detrimental effect of anaesthesia on the evenness of distribution of ventilation and blood flow in the lung.
The proposed study will have two parallel components or Parts. We wish to i) measure the magnitude of the second gas effects on both blood and expired concentrations of sevoflurane (Part 1), and ii) see if a demonstrable difference exists between the effects on blood and expired concentrations.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00321191
|Melbourne, Victoria, Australia, 3084|
|Principal Investigator:||Philip J Peyton, MD FANZCA||Austin Health|